财新传媒
财新英文 > 要闻 > 正文

In Depth: What’s Next for China’s Covid Vaccine Strategy?

By Zhao Jinzhao and Wang Xintong
2022年11月17日 19:33
Low take-up of first booster doses and a lack of more effective vaccines are the challenges to bolstering immunity, experts say
In September, China approved two Covid-19 vaccines for emergency use as heterologous boosters — vaccines that are different from the ones people use to complete their primary series of inoculations. Photo: VCG

China’s announcement to “optimize” its Covid strategy on Nov. 11 gave markets reasons to cheer and even led economics professor Liang Jianzhang to predict in a Caixin opinion piece that authorities would consider a full return to its pre-pandemic state.

The latest Covid response put forward 20 new guidelines including ending the “circuit breaker” mechanism for inbound flights and shortening the quarantine period for overseas travelers.

  [财新双语通产品,是为有双语需求读者专门订制的优惠产品, 按此可享超值优惠订阅。]

版面编辑:喻竹杨洋
财新网主编精选版电邮 样例
财新网新闻版电邮全新升级!财新网主编精心编写,每个工作日定时投递,篇篇重磅,可信可引。
订阅